CHR Citadelle Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4

Organization Overview

First Clinical Trial
2004
NCT00557817
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Centre Hospitalier Regional de la Citadelle | Centre Hospitalier Régional de la Citadelle | CHR Citadelle-CHU liège

Active Ingredients

Drugs in Phase 4 Trials (2)

acetylsalicylic acid (aspirin) (1 trial)

ketamine (ketalar) (1 trial)

Drugs in Phase 3 Trials (3)

acetylcysteine (mucomyst) (1 trial)

darbepoetin alfa (aranesp) (1 trial)

sucroferric oxyhydroxide (Venofer) (1 trial)

Drugs in Phase 2 Trials (1)

pyridostigmine bromide (mestinon) (1 trial)

Drugs in Other Trials (1)

wobenzyme (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia, Sickle Cell (Phase 3)

Atrophy (Phase 2)

Muscular Atrophy (Phase 2)

Muscular Atrophy, Spinal (Phase 2)

Neoplasms (Phase 3)

Spinal Muscular Atrophies of Childhood (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 6
  • # of Trial APIs: 7